In fact, clinicians who took a second look at x-rays using the deep learning software improved their sensitivity, on average, by 5.2%.

The updated guidelines suggest clinicians screen adults ages 50-75 who are at average risk for the disease, and discuss the benefits, harms and costs of the three screening methods prior to undertaking any one procedure.

The Ovarian-Adnexal Reporting and Data System combines a common North American approach with a widely used European algorithmic technique, created by an American College of Radiology-sponsored team.

A new AI algorithm developed by researchers at Case Western Reserve University can predict which malignant breast cancers will progress and benefit from additional treatment.

As of now the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has enrolled 16,505 participants across a number of certified mammography clinics in the U.S., Canada and Argentina, with more sites and participants to come.

“Because BI-RADS 3 breast lesions have up to 2% likelihood of malignancy, it is imperative that optimal follow-up of BI-RADS 3 test results be addressed...," authors of the new study published in JACR wrote.

In total, the groups released seven updated practice parameters that describe recommended procedures and considerations to safely administer radiation depending on practice area.

BI-RADS 4 lesions are considered among the most difficult and suspicious category of breast lesions.

Manufacturers, hospitals, physicians and patient advocates have put significant marketing resources—including millions of dollars—into selling 3D mammograms to women, despite little evidence the modality is better than traditional mammography.

“A better understanding of how age and comorbid conditions affect mammography use may help target specific populations and improve use of preventive care," wrote Cindy Yuan, MD, PhD, with the University of Chicago’s Department of Radiology, and colleagues.

The findings were true regardless of tumor type, size or cancer stage, wrote Pragya A. Dang, MD, and colleagues at Brigham and Women’s Hospital in Boston.

Men make up nearly 1% of all breast cancer cases in the U.S., but their mortality rate is drastically higher compared to women diagnosed with the disease.